UPDATE: Qiagen Q2 Revenues Bounce 9 Percent; Plans to Buy Back $100M in Shares | GenomeWeb

The story has been updated to include comments from Qiagen's conference call.

NEW YORK (GenomeWeb News) – Qiagen reported after the close of the market on Tuesday that revenues increased 9 percent year over year as both instruments and consumables and related sales bounced in the double digits.

The company also announced its first share buyback program with plans to repurchase up to $100 million in Qiagen shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.